HLA disparity is a major risk factor for graft rejection and GVHD. We report a patient with CML (accelerated phase) who underwent allogeneic SCT from a mismatched unrelated donor and developed acute GVHD. With immunosuppression, GVHD symptoms improved but graft rejection occurred. After a second conditioning regimen, the patient received a second graft from a haploidentical related donor. Engraftment occurred, but the patient died from GVHD and pulmonary aspergillosis. Chimeric analysis revealed that all leukocytes were of donor 2 origin apart from CD3+ T cells, which were 100% donor 1 type. Thus, in spite of intensified immunosuppression and successful transplantation of a second graft, T cells from the first donor persisted and induced severe acute GVHD.
graft rejection; chimerism; analysis; haploidentical transplant HLA disparity in allogeneic blood SCT is a major cause of severe complications such as graft rejection and GVHD. The incidence of graft rejection ranges from 2 to 30%, depending on the underlying disease, conditioning regimen, degree of HLA disparity, number of transplanted CD34+ cells and number of residual T cells. [1] [2] [3] [4] [5] The outlook remains poor for patients who undergo a second allogeneic transplant due to infectious complications. Here, we report a patient who experienced graft rejection of an allogeneic SCT from a mismatched unrelated donor and underwent second allogeneic transplantation from a haploidentical related donor. The patient developed severe acute GVHD after both stem cell transplants. Chimeric analysis demonstrated that even after graft rejection of the first graft and intensified immunosuppressive therapy for conditioning regimen prior to the second transplant, CD3+ T cells of the first donor persisted and induced severe acute GVHD.
Case report
A 42-year-old patient, with Philadelphia chromosome positive CML in first chronic phase in December 1995, was initially treated with hydroxyurea before interferon alpha was started. With no cytogenetic remission and intolerance to interferon, this was stopped in September 1997 and hydroxyurea was recommenced. As there was no HLA-matched related or unrelated donor available, allogeneic SCT was first discussed when in March/April 1999 peripheral blood and bone marrow examinations revealed accelerated phase CML, with 92% of metaphases showing a second Philadelphia chromosome. An unrelated donor was selected who showed a split difference in HLA-B and a subtype mismatch in the DRB1 locus:
HLA-A 24/32, B 38/60, DRB1 *11011/*1303 Donor 1: HLA-A 24/32, B 38/61, DRB1 *11011/*1301.
Antimicrobial prophylaxis was given as described previously. 6, 7 For conditioning, the patient received TBI (12 Gy) and cyclophosphamide (120 mg/kg). GVHD prophylaxis consisted of short-course methotrexate and CSA. To reduce the risk of graft rejection, ATG was administered (120 mg/kg). The patient received 6.5 Â 10 6 CD34+ PBSC from a mismatched unrelated donor and G-CSF was started on day +1. For severe acute GVHD involving skin, gut and liver (grade III) therapy with methylprednisolone (2 mg/kg) was started. Owing to progressive acute GVHD, the prednisolone dose was increased to 10 mg/kg and additional OKT3 (5 mg for 10 days) was administered 11 days after transplantation. Acute GVHD responded to the intensified immunosuppression, serum bilirubin levels fell from 42 to 6 mg/dl and acute GVHD of the skin improved significantly. After cessation of OKT3, CSA was replaced by FK506. Consecutively, the WBC fell below 100/ml. There was no evidence of a myelosuppressive viral infection and graft rejection was diagnosed on day +29 (confirmed by bone marrow cytology and histology). With no HLAidentical donor available and severe acute GVHD after the first transplant from a mismatched unrelated donor, the patient's 19-year-old daughter was recruited. She showed mismatches to the patient in the GVH direction in two HLA alleles (donor 2: HLA-A 24/32, B 18/38, DRB1 *11011/x). The patient underwent a second conditioning regimen with fludarabine (60 mg/m 2 ), total nodal irradiation (7 Gy) and OKT3 (6 Â 5 mg). At 36 days after the first allogeneic transplant, he received his second T-cell depleted graft consisting of 9.3 Â 10 6 CD34+ cells/kg with 1.4 Â 10 4 CD3+ cells/kg and 0.6 Â 10 4 CD56+ cells/kg. Following engraftment, acute GVHD of the skin occurred on day +13, and prednisolone was initiated (2 mg/kg). Additional PUVA therapy was started on day +20 for progressive cutaneous GVHD. A CT scan of the thorax on day +18 after the second transplant revealed pulmonary infiltrates with halo signs, highly suggestive of invasive pulmonary aspergillosis. Liposomal amphothericin B was therefore started. For progressive acute GVHD (epidermiolysis), the prednisolone dose was increased to 20 mg/kg. The patient finally became somnolent and died 26 days after second transplant due to uncontrolled severe acute GVHD and invasive aspergillosis.
Chimerism analysis
Post transplant chimerism was analyzed by a quantitative PCR approach for amplification of VNTR and STR markers, as recently described. 8 After identifying an informative locus, sequential patient peripheral blood samples were investigated. Serial densitometric analysis of PCR products allowed evaluation of the dynamics of posttransplant mixed chimerism. Chimerism status of peripheral blood on day +13, +20 and +23 after the second transplant showed no autologous cells, but simultaneous amplification with both donors (unrelated and related) revealed 95% of the peripheral blood cells to be from donor 2 and 5% from donor 1, on day +23. Analysis of the subpopulations demonstrated all subpopulations to be of donor 2 origin apart from all CD3+ cells, which were demonstrated to be exclusively derived from the first stem cell donor (Figure 1) .
Discussion
Until the introduction of STI, patients with intolerance to IFN or who had no cytogenetic remission were candidates for an allogeneic SCT from an unrelated donor due to the high risk to develop acceleration of CML within 5 years. 9, 10 At 4 years after the diagnosis of CML in first chronic phase, this patient progressed (second Philadelphia chromosome). Thus, the patient decided to undergo allogeneic SCT from a mismatched unrelated donor. As HLA disparity is known to be a major risk factor for graft rejection and acute GVHD, intensified immunosuppressive therapy was administered (ATG, CSA, MTX). Nevertheless, the patient developed severe acute GVHD and his immunosuppression was intensified (prednisolone, OKT3).
The GVHD symptoms improved, but 29 days after transplantation, graft rejection occurred. Owing to graft rejection and GVHD after the first allogeneic SCT, we decided to perform a second transplant from a different donor. To reduce the risk of reoccurrence of severe acute GVHD after the second transplant, we decided to T-cell deplete the stem cells from the haploidentical daughter. Despite T-cell depletion of the graft, stable engraftment occurred. Unfortunately, in spite of intensified GVHD prophylaxis, the patient developed severe acute GVHD. Chimeric analysis showed no autologous cells and all peripheral blood cells (apart from the CD3+ T cell population) derived from the second donor. Surprisingly, all detectable T cells (CD3+) were of donor 1 origin. In conclusion, T cells derived from the first donor induced severe acute GVHD after the second transplant as well, and persisted after two courses of OKT3 therapy, total nodal irradiation, fludarabine and high-dose prednisolone therapy as well as the second transplant from a mismatched related donor.
In summary, graft rejection, a 10-day course of OKT3 plus high-dose steroid therapy, and conditioning therapy consisting of fludarabine, OKT3, total nodal irradiation and prednisolone failed to completely eradicate the T-cells from the first donor. In contrast, persisting donor 1 derived T-cells expanded and induced severe acute GVHD in spite of engraftment of a second allogeneic stem cell transplant from a different donor. The persistence of the CD3+ T cells from the first donor might have been facilitated by the intensive T-cell depletion of the second stem cell graft.
In conclusion, patients undergoing a second T-cell depleted transplant from another donor might be at increased risk of severe acute GVHD induced by persisting T cells from the first donor. Thus, in spite of T-cell depletion of the second stem cell graft, intensified GVHD prophylaxis should be considered in view of the possibility of persisting T cells from the first donor associated with an increased risk of GVHD. The MW (molecular weight marker) is given in the first and the last lines. The second line shows the recipient pretransplant, in the second the patterns of donor 1 and in the third of donor 2. After the second transplant, chimerism analysis on day +17 revealed the presence of signals from donors 1 and 2. On day +20 after the second transplant, signals from the peripheral blood remained the same. In the CD 3+ enriched cells, however, only donor 1 specific signals could be seen.
